TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06472583

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Keytruda
Description: Preoperative immunotherapy (200 mg, infusion every 21 days, 4 administrations planned)

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Preoperative radiation therapy
Description: Boost of preoperative robotic stereotactic radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Preoperative radiation therapy
Description: Boost of preoperative robotic stereotactic radiotherapy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0,9% NaCl in the volume 100 ml
Study: NCT06584071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PM8002
Description: PM8002 via IV infusion, Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PM8002
Description: PM8002 via IV infusion, Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PM8002
Description: PM8002 via IV infusion, Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PM1009
Description: PM8002 via IV infusion, Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PM1009
Description: PM8002 via IV infusion, Q3W

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atezolizumab
Description: atezolizumab,1200mg, via IV infusion, Q3W

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bevacizumab
Description: bevacizumab,15mg/kg, via IV infusion, Q3W
Study: NCT05522049

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hyperangulated videolaryngoscope
Description: Intubation using a hyperangulated videolaryngoscope

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Macintosh videolaryngoscope
Description: Intubation using a Macintosh videolaryngoscope
Study: NCT05488665

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Crush technique
Description: Treatment for bifurcation with the Crush technique

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Culotte technique
Description: Treatment for bifurcation with the culotte technique
Study: NCT06404450

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital CBT
Description: The digital CBT program is called Daylight (Big Health, Ltd). The program employs a virtual therapist to guide individuals through interactive exercises and animations to facilitate the learning and implementation of CBT techniques. The program focuses on four modules (10-20 minutes each) which address specific CBT principles: stimulus control, applied relaxation, cognitive restructuring (decatastrophizing), and imaginal exposure. Daylight is designed to be self-paced, with the app encouraging users to practice techniques both within the app and in real-life situations on a daily basis. Users receive reminders and motivational messages via emails, push notifications, and text messages tailored to participant progress.
Study: NCT06088121

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ATNC MDD-V1 (Real TMS + Real Cog)
Description: Synchronized TMS and cognitive stimulation to 6 brain areas.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: ATNC MDD-V1 (Sham TMS + Real Cog)
Description: Sham device, has the same appearance and sound as the real device, combined with real cognitive exercises. Patients come for the same number of sessions, delivers no real stimulation or cognitive training.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ATNC BN-V1
Description: The navigation system is used to determine the exact brain location to be stimulated (coordinates for the stimulation point).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: ATNC BN-V1
Description: The navigation system is used to determine the exact brain location to be stimulated (coordinates for the stimulation point).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ATNC BN-V2
Description: The navigation system is used to determine the exact brain location to be stimulated (coordinates for the stimulation point).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: ATNC BN-V2
Description: The navigation system is used to determine the exact brain location to be stimulated (coordinates for the stimulation point).
Study: NCT06120127

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: postoperative SBRT of liver lesions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: XELOX/FOLFOX/FOLFIRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: XELOX/FOLFOX/FOLFIRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 antibody
Description: Sintilimab (200mg d1，q3w)
Study: NCT04792528

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computerized cognitive training.
Description: COGMED RM program (Pearson Inc., UK)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computerized cognitive training.
Description: COGMED RM program (Pearson Inc., UK)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Generalized brain training / Active control
Description: Solitaire
Study: NCT06496763

Intervention type: DEVICE
Intervention: Vision-700
Description: OCT machines used for diagnostic purposes
Study: NCT05386420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hymecromone tablets
Description: Conventional treatment combined with Hymecromone tablets, 0.4g , tid ac, 7 days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Conventional treatment combined with Placebo.
Study: NCT05108012

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NK cell therapy
Description: Activated NK cell injection in tumor cavity of patient with GBM (Glioblastoma Multiform)
Study: NCT06137937

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: Intradialytic aerobic exercise for eight weeks
Study: NCT05811286

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hysteroscopic morcellation 19 Fr. intrauterine BIGATTI Shaver for uterine intracavitary lesions
Description: With the shaver, the lesion is removed in the OR. We will include endometrial polyps, FIGO 0-1 myomas and retained products of conception.~We will assess the completeness of hysteroscopic resection, operation time, need for cervical dilation, adverse events, pain, operator satisfaction; quality of tissue for histological examination, postoperative complications and pain.
Study: NCT05993858

Intervention type: DRUG
Group type: OTHER
Intervention: 3cycles (Toripalimab + cetuximab)
Description: Toripalimab by intravenous (IV) infusion every 3 weeks (Q3W), 3 preoperative and 17 consolidated doses.~The preoperative starting dose of cetuximab is 400 mg/m\^2 by IV infusion over 120 minutes for 1 week, subsequently followed by 250 mg/m\^2 IV infusion over 60 minutes, from week 2 to 9.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Surgery
Description: After neoadjuvant therapy, patients would accept surgery within 11-13 weeks.

Intervention type: RADIATION
Group type: OTHER
Intervention: Radiotherapy or chemoradiotherapy
Description: Adjuvant radiotherapy was given 4 weeks after surgery. Patients with positive intraoperative pathological margins/extra lymph node envelope invasion are treated with an additional cisplatin synchronous chemotherapy.
Study: NCT04805034

Intervention type: OTHER
Intervention: Age, BMI,Baseline HBV DNA, Baseline HBeAg level, Baseline HBsAg level, Antiviral treatment, Serum ALT level
Description: Exposure factors: Age, BMI, Family history, Baseline HBV DNA, Baseline HBeAg level, Baseline HBsAg level, Antiviral treatment, Serum ALT level
Study: NCT04841512

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: XT-150
Description: non-viral Plasmid DNA encoding an IL-10 variant transgene

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: XT-150
Description: non-viral Plasmid DNA encoding an IL-10 variant transgene

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: XT-150
Description: non-viral Plasmid DNA encoding an IL-10 variant transgene
Study: NCT05029414

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endovascular Therapy
Description: Endovascular treatment of stroke is the non-surgical treatment for the sudden loss of brain function due to blood clots. The blood clot is removed from the blood via devices (i.e. stent-retriever, aspiration catheters and balloon guide) to achieve revascularization.
Study: NCT06035991

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Heart transplantation
Description: Heart transplantation in patients who have obtained a favourable and motivated opinion from the Multidisciplinary Consultation Meeting (RCP) of the cardiac surgery department of the Hospital Pitié-Salpêtrière
Study: NCT05231486

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Orientation to daily Occupational Performance
Description: CO-OP uses cognitive problem solving techniques to facilitate motor skill acquisition. The therapist facilitates with guided discovery the child to generate solution for problems in their performance areas.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Orientation to daily Occupational Performance
Description: CO-OP uses cognitive problem solving techniques to facilitate motor skill acquisition. The therapist facilitates with guided discovery the child to generate solution for problems in their performance areas.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Orientation to daily Occupational Performance
Description: CO-OP uses cognitive problem solving techniques to facilitate motor skill acquisition. The therapist facilitates with guided discovery the child to generate solution for problems in their performance areas.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Orientation to daily Occupational Performance
Description: CO-OP uses cognitive problem solving techniques to facilitate motor skill acquisition. The therapist facilitates with guided discovery the child to generate solution for problems in their performance areas.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Orientation to daily Occupational Performance
Description: CO-OP uses cognitive problem solving techniques to facilitate motor skill acquisition. The therapist facilitates with guided discovery the child to generate solution for problems in their performance areas.
Study: NCT04509960

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: direct laryngoskopy
Description: Proseal Laryngeal mask inserted with direct laryngoskopy
Study: NCT05913310

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Kui-Yuan Chewable Tablets
Description: Kui-Yuan chewable tablets are the optimal ingredients found in sunflower dish that can reduce uric acid and anti-gout, including flavonoids, Coumarin (including scopolamine) and phenolic acids.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placedo of Kui-Yuan Chewable Tablets
Description: Placedo of Kui-Yuan Chewable Tablets are composed of L-arabinose, food starch and a few auxiliary materials.
Study: NCT05106504

Intervention type: DRUG
Intervention: Medical Cannabis
Description: Patients will be assessed before and after use of Medical cannabis via inhaled dried buds or sublingual oil extract
Study: NCT05274802

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALS-4
Description: Single dose of ALS-4 before Breakfast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALS-4
Description: Single dose of ALS-4 before Breakfast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALS-4
Description: Single dose of ALS-4 before Breakfast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALS-4
Description: Single dose of ALS-4 before Breakfast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALS-4
Description: Single dose of ALS-4 before Breakfast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single dose of placebo before Breakfast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single dose of placebo before Breakfast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single dose of placebo before Breakfast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single dose of placebo before Breakfast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single dose of placebo before Breakfast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single dose of placebo before Breakfast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALS-4
Description: Dose three separate times in crossover fashion: (1) fasted morning dose; (2) fed morning dose; (3) fasted evening dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALS-4
Description: Multiple dose of ALS-4 up to two times daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALS-4
Description: Multiple dose of ALS-4 up to two times daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALS-4
Description: Multiple dose of ALS-4 up to two times daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Multiple dose of placebo up to two times daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Multiple dose of placebo up to two times daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Multiple dose of placebo up to two times daily
Study: NCT05578495

Intervention type: OTHER
Group type: OTHER
Intervention: Accelerometer data
Description: Patients will wear an accelerometer 3 times a year for 5 days (3 weekdays and 2 weekend days), the data will be collected
Study: NCT05532449

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous dizocine
Description: Intravenous dizocine (0.03mg/kg diluted to 5 ml)
Study: NCT05426642

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-health Video KaSEH
Description: The e-health video KaSEH is produce based on Protection Motivation Theory to enhance women's motivation towards cervical cancer screening.

Intervention type: OTHER
Group type: OTHER
Intervention: Brochure
Description: The brochure contain the information regarding cervical cancer and its screening

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brochure
Description: The brochure contain the information regarding cervical cancer and its screening
Study: NCT05944042

Intervention type: OTHER
Intervention: Observational Transplant Analysis
Description: Identify more accurate predictive models of transplant risk

Intervention type: OTHER
Intervention: Observational Transplant Analysis
Description: Identify more accurate predictive models of transplant risk
Study: NCT05712135

Intervention type: OTHER
Intervention: supine position
Description: The patient group whose cuff pressure was measured in the supine position

Intervention type: OTHER
Intervention: prone position
Description: The patient group whose cuff pressure was measured in the prone position

Intervention type: OTHER
Intervention: semi-fowler position
Description: The patient group whose cuff pressure was measured in the semi-fowler position
Study: NCT05214170

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electroanatomic mapping with the NeuTrace System
Description: Patients with arrhythmias undergo electroanatomic mapping with the NeuTrace System.
Study: NCT06494787

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Aliya Pulse Electric Field sysem and pembrolizumab
Description: This is a phase 2 study to determine the efficacy of the Aliya Pulse Electric Field system and pembrolizumab in prolonging progression free and overall survival of patients with advanced soft tissue sarcoma
Study: NCT04919252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab
Description: * Crohn's disease (CD): If a subject does not respond to vedolizumab 300mg iv 0, 2, and 6 weeks for induction, an additional dose of vedolizumab 300 mg will be given at week 10. On the other hand, Maintenance therapy should be continued every 8 weeks from week 14 in responding patients, and for some patients who have experienced a decrease in their response, it can be given every 4 weeks. The maximum dosing period is 54 weeks.~* Ulcerative colitis (UC): If a subject responds to vedolizumab 300mg iv 0, 2, and 6 weeks for induction, maintenance therapy should be continued every 8 weeks from week 14, and for some patients who have experienced a decrease in their response, it can be given every 4 weeks. The maximum dosing period is 54 weeks.
Study: NCT05921396

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nasal patency - rhinomanometry
Description: Nasal patency before and after the pituitary adenoma surgery will be assessed using rhinomanometry.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nasal patency - nasal inspiratory peak flow
Description: Nasal patency before and after the pituitary adenoma surgery will be assessed using nasal inspiratory peak flow..
Study: NCT04910477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: ultrasonic nebulization of dexmedetomidine (1 mg/kg diluted in 4 mL saline) twice daily for three days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neostigmine/atropine
Description: nebulization of 20 µ/kg neostigmine and 10 µ/kg atropine mixed in 4 ml) twice daily for three days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline placebo
Description: nebulization of saline placebo in 4 ml) twice daily for three days.
Study: NCT05217693

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BB-1705
Description: BB-1705 is an ADC consisting of an engineered humanized IgG1κ monoclonal antibody conjugated to the cytotoxic agent eribulin via a cathepsin-cleavable valine-citrulline linker. BB-1705 has a molecular weight of approximately 152 kDa, including two molecules of eribulin via the linker.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BB-1705
Description: BB-1705 is an ADC consisting of an engineered humanized IgG1κ monoclonal antibody conjugated to the cytotoxic agent eribulin via a cathepsin-cleavable valine-citrulline linker. BB-1705 has a molecular weight of approximately 152 kDa, including two molecules of eribulin via the linker.
Study: NCT04645771

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Questionnaires to assess the quality of life (EQ-5D, CVVQ, CIVIQ, AVVQ, Patient satisfaction survey)
Study: NCT04998487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3471851
Description: Administered SC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3471851
Description: Administered SC.
Study: NCT05710926

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Evolutionary Systems Therapy for Schizotypy
Description: A novel therapy for schizotypal traits integrating evolutionary psychopathology, compassion focused therapy, and metacognitively oriented psychotherapy.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy
Description: An adaptation of Cognitive Behavioral Therapy for those diagnosed with personaloty disorders.
Study: NCT05356468

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Structured pain neuroscience education
Description: Structured pain neuroscience~* Neurophysiology of pain~* The PNE occurred with the use of pictures, examples, metaphors and drawings as needed~* Metaphor Alarm system: Your nerves working like an alarm system to protect you.~* BOOKLET Consist of education about pain neurophysiology.(31)~* Steps of booklet :~  1. Extract content~ 2. English to Urdu translation~ 3. Content Validity~ 4. Expert Panel review by Physiotherapists~ 5. Content validity Analysis review(Focus Group)~ 6. Pilot study 4 to 5 patients~ 7. Content improved (PNE) and Finalized~ 8. After Analysis RCT

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Treatment
Description: ELECTROTHERAPY MODALTIES-15 min~* IFC (interferential current)IFC will be administered using following parameters: 80-150 watts, 4000 Hz, sweep on, 16.0-17.0 CV(26)~* Hot pack(27)~Therapeutic exercises~* Strengthening (Back extensors, quadriceps, hamstring and VMO, gluteus maximums, gluteus medius, transverse abdominis.~* Stretching hamstring and, calf stretching. Soft tissue mobilization(5) McKenzie based exercises(28) BALANCE EXERCISES~* Single Leg Stance (static balance) Patient is instructed to stand on one leg,close his/her eyes and maintain this position as long as they could.~* Tandem gait (dynamic balance) patient is instructed to walk a total of 5 laps on a 2-meter-long line with the heel of the front foot touching the fingertip of the back foot.(29)~POSTURAL TRAINING~* good posture when sitting standing and while driving~* Avoid weight lifting~* Avoid too much bed rest~* Sit in firm places. (30)
Study: NCT06374914

Intervention type: DRUG
Intervention: Intravesical Solution
Description: Alkalinization of urine 1 day before the procedure Emptying the bladder with a catheter before the procedure mixing 1000 mg gemcitabine in 50 ml saline 90 minutes after administration 37.5 mg docetaxel mixed 120 minutes after administration in 50 ml saline maintanence if there is a 6 week induction response
Study: NCT06375434

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT04981821

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GO-EXCAP Mobile App
Description: A mobile app delivery platform to deliver an exercise program \[Exercise for Cancer Patients (EXCAP©®)\]. EXCAP©®) is a progressive walking and resistance exercise program

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Placebo Control
Description: Participants will meet with an oncology nurse (for approximately 60 min) to review the NCI booklet Chemotherapy and You: Support for People With Cancer, which includes facts about chemotherapy and its side effects. They will be provided with NCI online resources to review at home.
Study: NCT04801134

Intervention type: OTHER
Group type: OTHER
Intervention: Education
Description: as per previous description
Study: NCT05173142

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMPL-453
Description: HMPL-453 administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMPL-453
Description: HMPL-453 administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine and cisplatin
Description: Gemcitabine and Cisplatin administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine and cisplatin
Description: Gemcitabine and Cisplatin administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: toripalimab
Description: Toripalimab administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: toripalimab
Description: Toripalimab administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel administered intravenously.